Shire Debuts MYDAYIS® and New Research at the 30th Annual Psych Congress

Lexington, MA – September 15, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) will share new Attention Deficit Hyperactivity Disorder (ADHD) research at the upcoming Psych Congress in New Orleans, Louisiana from September 16-19, 2017. Research will include findings about MYDAYIS^® (mixed salts of a single-entity amphetamine product), which was recently approved by the U.S. Food and Drug Administration (FDA) as a once-daily treatment comprised of three different types of drug-releasing beads for patients 13 years and older with ADHD. Mydayis is not for use in children 12 years and younger.

“Shire continues to advance our 20 years of ADHD scientific commitment and leadership through new data and evidence generation. In addition to our outcomes and working to address the evolving needs of ADHD patients, Shire will present new research at this year’s Psych Congress focusing on the efficacy and safety profile of Mydayis,” said Manisha Madhoo, MD, Vice President of Global Medical Affairs, Neuroscience, Shire. “Our focus at the Psych Congress will be to provide information to healthcare professionals who may have questions about the recently FDA approved treatment, Mydayis, and how it may be a tool they can use in their clinical practices for appropriate patients.”

In addition to presenting new research, Shire is sponsoring a panel moderated by Dr. Jennifer Ashton, ABC News’ Chief Women’s Health Correspondent to discuss a new treatment option and the individual needs of adult patients with ADHD. Shire will also have a branded booth where attendees will be able to speak to representatives, learn more about Shire products and the company’s commitment to the ADHD community.

 For more information please read the full press release on Shire's website